Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.

Applied immunohistochemistry & molecular morphology : AIMM - 1 Mar 2014

Adams Julia A, Post Kristin M, Bilbo Sarah A, Wang Xiaoyan, Sen Joyashree D, Cornwell Anita J, Malek Amanda J, Cheng Liang

Abstract excerpt

The identification of KRAS mutations in patients with certain types of cancer, including colonic adenocarcinoma and non-small cell lung carcinoma, has become increasingly important as these patients are contraindicated from receiving epidermal growth factor receptor-targeted therapies. Several polymerase chain reaction (PCR)-based tests are commercially available for KRAS mutation testing including Applied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Reagent Kits, Diagnostic

Source

Identifiers

PMID: 24614151
DOI: 10.1097/PDM.0b013e3182a127f9

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.PMID 24614151Read ↗

QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens.Semantic proximity Read ↗

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.Semantic proximity Read ↗

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.Semantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

KRAS mutation analysis by PCR: a comparison of two methods.Semantic proximity Read ↗

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceSemantic proximity Read ↗

Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.Semantic proximity Read ↗

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.Semantic proximity Read ↗

A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical SettingSemantic proximity Read ↗

A comparability study of 5 commercial KRAS tests.Semantic proximity Read ↗

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.Semantic proximity Read ↗

BRAF mutation testing in solid tumors: a methodological comparison.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.